Biotech Values

[RockRat]

NTGN A quick look shows little in the way of catalysts for the precipitous drop from IPO price, and this well before lock up expiration. Obviously, I haven't been following it. It can't just be managerial credibility, or this wouldn't have IPOed in the first place; the buysiders aren't that gullible. Has recent clinical data from someone else' program(s) obviated their approach or something?

TIA & Regards RockRat